obesity

News

AstraZeneca builds in obesity with $2bn+ Eccogene deal

AstraZeneca headlined its third-quarter earnings update with news of a $185 million upfront licensing deal with Chinese biotech Eccogene for an orally active GLP-1 agonist

News

Lilly gets FDA okay for tirzepatide as obesity therapy

Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a

News

Novo Nordisk shrugs off supply issues with record sales

Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growt

News

Boehringer moves obesity therapy into phase 3

Boehringer Ingelheim and Zealand Pharma have kicked off three phase 3 trials of obesity drug candidate survodutide, in patients with and without diabetes, in the hope of b

R&D

GLP-1 weight loss drugs: An overview and update

GLP-1 agonists like Ozempic, Wegovy, and Mounjaro are dramatically changing the field of medically-assisted weight loss.

News

Wegovy finally reaches the UK, in 'limited' quantities

Novo Nordisk's sought-after obesity therapy Wegovy has finally reached the UK and can be prescribed by NHS weight management services – but supplies are being carefully co

AstraZeneca builds in obesity with $2bn+ Eccogene deal

Lilly gets FDA okay for tirzepatide as obesity therapy

Novo Nordisk shrugs off supply issues with record sales

Boehringer moves obesity therapy into phase 3

GLP-1 weight loss drugs: An overview and update

Wegovy finally reaches the UK, in 'limited' quantities

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

obesity

Editor's Picks